How Comprehensive Drug Policies Build Trust in Local Governments
Episode Overview
Comprehensive drug policies can increase public trust in local governments. Treating insomnia may improve outcomes for those recovering from opioid use disorder. Substance use disorder mortality hotspots have shifted from rural to urban areas over time. Delta-8 THC has similar effects to Delta-9 THC at higher doses. Psychedelic drug use may enhance creativity and feelings of connectedness.
Public trust was positively associated with increased perception of government support for comprehensive drug policies
Ever wondered how comprehensive drug policies can impact public trust in local governments? This episode of 'This Week in Addiction Medicine' from the American Society of Addiction Medicine (ASAM) dives into the heart of this topic, focusing on rural US Appalachian and Midwestern counties. The discussion is rooted in two studies that explore how residents' perceptions of government support for harm reduction policies can influence their trust in local authorities.
The findings suggest that such policies may actually bolster public trust, challenging the fear of backlash. But that's just the beginning. The episode also touches on insomnia's role in opioid use disorder recovery, revealing that treating insomnia could significantly improve outcomes. You'll also hear about shifting substance use disorder mortality hotspots in the US, the effects of Delta-8 THC compared to Delta-9 THC, and lessons from drug decriminalisation efforts in British Columbia.
Plus, there's an intriguing look at how cannabis might be linked to psychosis through the dopamine system, and a fascinating dive into the history of alcohol research with Richardson's Law. Finally, the episode explores how psychedelic drug use may enhance creativity and connectedness. With a blend of scientific research and practical insights, this episode is a must-listen for anyone interested in addiction medicine and public health policy.
Why not give it a go and see how these findings might change your perspective on drug policies and their broader implications?